YK-4-279

YK-4-279 blocks RNA Helicase A (RHA) binding with EWS-FLI1 (oncogenic protein) . YK-4-279 induces apoptosis and shows anti-proliferation activities towards various cancer cells. YK-4-279 has a chiral center and it can be separated into two enantiomers. YK-4-279 can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[1037184-44-3]

UNSPSC

12352005

Hazard Statement

H302, H317

Target

Apoptosis; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/YK-4-279.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

ClC1=C2C(C(O)(CC(C3=CC=C(OC)C=C3)=O)C(N2)=O)=C(Cl)C=C1

Molecular Formula

C17H13Cl2NO4

Molecular Weight

366.20

Precautions

H302, H317

References & Citations

[1]Erkizan HV, et al. A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med. 2009 Jul;15 (7) :750-6.|[2]Barber-Rotenberg JS, et al. Single enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1. Oncotarget. 2012 Feb;3 (2) :172-82.